CRESO PHARMA LIMITED - Corporate Spotlight

Currently unlisted. Add to my watchlist

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people... Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.More

Corporate Spotlight

CPH POSTS 77% REVENUE JUMP IN Q3

LATEST FROM CPH

Creso Pharma’s (ASX:CPH) Halucenex doses first patient in phase two psilocybin clinical trial

ASX:CPH

07 December 2022 18:32 (AEDT)

Creso Pharma’s (CPH) Canadian-based subsidiary, Halucenex Life Sciences, administers the first dose of its synthetic psilocybin product in a phase two clinical trial
The first of 20 participants received both doses of the Lucenex-branded drug, initially a 10-milligram dose, followed by a macrodose of 25 milligrams in a separate session
The trial is assessing the efficacy of the drug on treatment-resistant PTSD, and the remaining patients will receive the same dosages at a rate of two patients per week
Halucenex is also looking to amend the trial to investigate sleep disruption as one of the most impactful symptoms of PTSD
Read the Full Article on The Market Herald here

VIDEO & MEDIA

Creso Pharma (ASX:CPH) eyes expansion in South Korea

Creso Pharma (ASX:CPH) eyes entrance to Taiwanese animal healthcare market

Creso Pharma (ASX:CPH) eyes Australian body care market with Dr Pickles deal

Creso Pharma (ASX:CPH) accelerates strategic expansion after record quarter results

CPH ANNOUNCES PLANS TO ENTER US CBD MARKET

Creso Pharma (ASX:CPH) ends June quarter with revenue growth

Creso Pharma (ASX:CPH) shares jump on record revenue growth

Creso Pharma (ASX:CPH) announces merger with Red Light Holland

Creso Pharma (ASX:CPH) completes US dual listing

(ASX:CPH) Halucenex secures additional 10 grams of psilocybin

Creso Pharma (ASX:CPH) secures commitments to raise nearly $9M

ABOUT US

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

To learn more please visit: www.cresopharma.com